Therapeutic approaches to target alpha-synuclein pathology

Experimental Neurology

Volumn 298, Issue , 2017, Pages 225-235

  Brundin, Patrik ^a   Dave, Kuldip D ^b   Kordower, Jeffrey H ^a,c  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha synuclein; Biomarker; Clinical Trial; Dementia with Lewy bodies; Immunotherapy; Multiple system atrophy; Parkinson's disease; Protein aggregation; Therapy

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

CELL LEVEL; DRUG TARGETING; EXTRACELLULAR SPACE; HUMAN; MOLECULAR PATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEINOSIS; REVIEW; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PROCEDURES; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HUMANS; MULTIPLE SYSTEM ATROPHY; NEURONS; PARKINSON DISEASE;

EID: 85030710090     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2017.10.003     Document Type: Review

References (131)

1. Affiris Company Website, AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE® PD03A, confirming immunogenicity and safety profile in Parkinson's disease patients. www.affiris.comnewsaffiris-announces-top-line-results-of-first-in-human-clinical-study-using-affitope, 2017.
2. Alzforum, α-Synuclein antibodies enter phase 2, sans biomarker. http://www.alzforum.org/news/conference-coverage/synuclein-antibodies-enter-phase-2-sans-biomarker, 2017.
3. Barbour, R., Kling, K., Anderson, J.P., Banducci, K., Cole, T., Diep, L., Fox, M., Goldstein, J.M., Soriano, F., Seubert, P., Chilcote, T.J., Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5 (2008), 55–59, 10.1159/000112832.
4. Bartels, T., Choi, J.G., Selkoe, D.J., α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 (2011), 107–110, 10.1038/nature10324.
5. Beach, T.G., White, C.L., Hladik, C.L., Sabbagh, M.N., Connor, D.J., Shill, H.A., Sue, L.I., Sasse, J., Bachalakuri, J., Henry-Watson, J., Akiyama, H., Adler, C.H., Arizona Parkinson's Disease Consortium, Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117 (2009), 169–174, 10.1007/s00401-008-0450-7.
6. Bendor, J.T., Logan, T.P., Edwards, R.H., The function of α-synuclein. Neuron 79 (2013), 1044–1066, 10.1016/j.neuron.2013.09.004.
7. Béraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., Federoff, H.J., Shimoji, M., Mhyre, T.R., Maguire-Zeiss, K.A., Microglial Activation and Antioxidant Responses Induced by the Parkinson's Disease Protein α-synuclein. J Neuroimmune Pharmacol 8 (2013), 94–117, 10.1007/s11481-012-9401-0.
8. Bhatt, M.A., Messer, A., Kordower, J.H., Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis 3 (2013), 581–591, 10.3233/JPD-130252.
9. BioArctic Company Website, BioArctic enters into collaboration with AbbVie for Parkinson's disease research. https://www.bioarctic.se/en/bioarctic-enters-into-collaboration-with-abbvie-for-parkinsons-disease-research-2815/, 2016.
10. Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P.H., Habenstein, B., Madiona, K., Olieric, V., Böckmann, A., Meier, B.H., Melki, R., Structural and functional characterization of two alpha-synuclein strains. Nature Communications, 4, 2013, 2575, 10.1038/ncomms3575.
11. Braak, H., Del Tredici, K., Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis 7 (2017), S71–S85, 10.3233/JPD-179001.
12. Brahmachari, S., Karuppagounder, S.S., Ge, P., Lee, S., Dawson, V.L., Dawson, T.M., Ko, H.S., c-Abl and Parkinson's disease: mechanisms and therapeutic potential. J Parkinsons Dis, 2017.
13. Brundin, P., Ma, J., Kordower, J.H., How strong is the evidence that Parkinson's disease is a prion disorder?. Curr. Opin. Neurol. 29 (2016), 459–466, 10.1097/WCO.0000000000000349.
14. Brys, M., Hung, S., Fanning, L., Penner, N., Yang, M., David, E., Fox, T., Makh, S., Graham, D., Cedarbaum, J.M., Randomized, double-blind, placebo-controlled, single ascending dose study of anti-alpha-synuclein antibody BIIB054 in healthy volunteers. 2017.
15. Burré, J., The Synaptic Function of α-synuclein. J Parkinsons Dis 5 (2015), 699–713, 10.3233/JPD-150642.
16. Burré, J., Sharma, M., Südhof, T.C., Cell Biology and Pathophysiology of α-synuclein. Cold Spring Harb Perspect Med, 2017, a024091–29, 10.1101/cshperspect.a024091.
17. Chan, K.Y., Jang, M.J., Yoo, B.B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S.K., Deverman, B.E., Gradinaru, V., Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20 (2017), 1172–1179, 10.1038/nn.4593.
18. Chu, Y., Kordower, J.H., Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiol Dis 25 (2007), 134–149, 10.1016/j.nbd.2006.08.021.
19. ClinicalTrials.gov Identifier: NCT02914366. Ambroxol as a treatment for Parkinson's disease dementia. https://clinicaltrials.gov/ct2/show/NCT02914366?cond=Ambroxol&draw=1&rank=3.
20. ClinicalTrials.gov Identifier: NCT02941822. Ambroxol in Disease Modification in Parkinson Disease (AiM-PD) https://clinicaltrials.gov/ct2/show/NCT02941822?cond=Ambroxol&draw=1&rank=6.
21. Coetzee, S.G., Pierce, S., Brundin, P., Brundin, L., Hazelett, D.J., Coetzee, G.A., Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. Sci. Rep., 6, 2016 srep30509 https://doi.org/10.1038/srep30509.
22. Collier, T.J., Redmond, D.E., Steece-Collier, K., Lipton, J.W., Manfredsson, F.P., Is alpha-synuclein loss-of-function a contributor to Parkinsonian pathology? Evidence from non-human primates. Front Neurosci, 10, 2016 239–7 https://doi.org/10.3389/fnins.2016.00012.
23. Cookson, M.R., alpha-Synuclein and neuronal cell death. Mol. Neurodegener., 4, 2009, 9, 10.1186/1750-1326-4-9.
24. De Genst, E.J., Guilliams, T., Wellens, J., O'Day, E.M., Waudby, C.A., Meehan, S., Dumoulin, M., Hsu, S.-T.D., Cremades, N., Verschueren, K.H.G., Pardon, E., Wyns, L., Steyaert, J., Christodoulou, J., Dobson, C.M., Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. J Mol Biol 402 (2010), 326–343, 10.1016/j.jmb.2010.07.001.
25. Decressac, M., Björklund, A., TFEB: Pathogenic role and therapeutic target in Parkinson disease. Autophagy 9 (2013), 1244–1246, 10.4161/auto.25044.
26. Decressac, M., Kadkhodaei, B., Mattsson, B., Laguna, A., Perlmann, T., Björklund, A., α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons. Sci. Transl. Med., 4, 2012 163ra156 https://doi.org/10.1126/scitranslmed.3004676.
27. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., Björklund, A., TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci USA 110 (2013), E1817–26, 10.1073/pnas.1305623110.
28. Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C.W., Merchant, K.M., Bezard, E., Petsko, G.A., Meissner, W.G., Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 14 (2015), 855–866, 10.1016/S1474-4422(15)00006-X.
29. Del Tredici, K., Braak, H., Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol 42 (2016), 33–50, 10.1111/nan.12298.
30. Dufty, B.M., Warner, L.R., Hou, S.T., Jiang, S.X., Gómez-Isla, T., Leenhouts, K.M., Oxford, J.T., Feany, M.B., Masliah, E., Rohn, T.T., Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170 (2007), 1725–1738, 10.2353/ajpath.2007.061232.
31. Eberling, J.L., Dave, K.D., Frasier, M.A., α-Synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis 3 (2013), 565–567, 10.3233/JPD-130247.
32. Espay, A.J., Brundin, P., Lang, A.E., Precision medicine for disease modification in Parkinson disease. Nat. Rev. Neurol., 2016.
33. Espay, A.J., Schwarzschild, M.A., Tanner, C.M., Fernandez, H.H., Simon, D.K., Leverenz, J.B., Merola, A., Chen-Plotkin, A., Brundin, P., Kauffman, M.A., Erro, R., Kieburtz, K., Woo, D., Macklin, E.A., Standaert, D.G., Lang, A.E., Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord 32 (2017), 319–324, 10.1002/mds.26913.
34. Fagerqvist, T., Lindström, V., Nordström, E., Lord, A., Tucker, S.M.E., Su, X., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., Näsström, T., Holmquist, M., Schell, H., Kahle, P.J., Kalimo, H., Möller, C., Gellerfors, P., Lannfelt, L., Bergström, J., Ingelsson, M., Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation. J Neurochem 126 (2013), 131–144, 10.1111/jnc.12175.
35. Fairfoul, G., McGuire, L.I., Pal, S., Ironside, J.W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S.G., Rolinski, M., Baig, F., Ruffmann, C., Wade-Martins, R., Hu, M.T.M., Parkkinen, L., Green, A.J.E., Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol, 2016, 1–7, 10.1002/acn3.338.
36. Fauvet, B., Mbefo, M.K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M.T., Tsika, E., Coune, P., Prudent, M., Lion, N., Eliezer, D., Moore, D.J., Schneider, B., Aebischer, P., El-Agnaf, O.M., Masliah, E., Lashuel, H.A., α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287 (2012), 15345–15364, 10.1074/jbc.M111.318949.
37. Febbraro, F., Sahin, G., Farran, A., Soares, S., Jensen, P.H., Kirik, D., Romero-Ramos, M., Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis 56 (2013), 47–58.
38. Freeman, D., Cedillos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A.M., Sudholt, S., Rana, A., O'Connor, C., Wiethoff, C.M., Campbell, E.M., Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS ONE, 8, 2013, e62143, 10.1371/journal.pone.0062143.
39. Gao, H.-M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojanowski, J.Q., Lee, V.M.-Y., Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28 (2008), 7687–7698, 10.1523/JNEUROSCI.0143-07.2008.
40. George, S., Brundin, P., Immunotherapy in Parkinson's Disease: Micromanaging Alpha-synuclein Aggregation. J Parkinsons Dis 5 (2015), 413–424, 10.3233/JPD-150630.
41. George, S., Brundin, P., Solving the conundrum of insoluble protein aggregates. Lancet Neurol 16 (2017), 258–259, 10.1016/S1474-4422(17)30045-5.
42. Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S.R., Jangamreddy, J.R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A.R., Kashani, H.H., Hashemi, M., Owji, A.A., Łos, M.J., Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 112 (2014), 24–49, 10.1016/j.pneurobio.2013.10.004.
43. Ghosh, A., Tyson, T., George, S., Hildebrandt, E.N., Steiner, J.A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W.G., Escobar Galvis, M.L., Kordower, J.H., Van Raamsdonk, J.M., Colca, J.R., Brundin, P., 2016. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Science Translational Medicine 8, 368ra174–368ra174. doi: https://doi.org/10.1126/scitranslmed.aag2210.
44. Goedert, M., Masuda-Suzukake, M., Falcon, B., Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140 (2017), 266–278, 10.1093/brain/aww230.
45. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P., Muzyczka, N., In Vivo RNAi-Mediated α-synuclein Silencing Induces Nigrostriatal Degeneration. Mol Ther 18 (2010), 1450–1457, 10.1038/mt.2010.115.
46. Gorenberg, E.L., Chandra, S.S., The Role of Co-chaperones in Synaptic proteostasis and Neurodegenerative Disease. Front Neurosci, 11, 2017, 248, 10.3389/fnins.2017.00248.
47. Guo, J.L., Lee, V.M.-Y., Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nature Medicine 20 (2014), 130–138, 10.1038/nm.3457.
48. Guo, J.L., Covell, D.J., Daniels, J.P., Iba, M., Stieber, A., Zhang, B., Riddle, D.M., Kwong, L.K., Xu, Y., Trojanowski, J.Q., Lee, V.M.-Y., Distinct α-synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell 154 (2013), 103–117, 10.1016/j.cell.2013.05.057.
49. Halliday, G.M., Holton, J.L., Revesz, T., Dickson, D.W., Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122 (2011), 187–204, 10.1007/s00401-011-0852-9.
50. Hebron, M.L., Lonskaya, I., Moussa, C.E.H., Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models. Hum Mol Genet 22 (2013), 3315–3328, 10.1093/hmg/ddt192.
51. Holmes, B.B., Devos, S.L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M.O., Brodsky, F.M., Marasa, J., Bagchi, D.P., Kotzbauer, P.T., Miller, T.M., Papy-Garcia, D., Diamond, M.I., Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110 (2013), E3138–47, 10.1073/pnas.1301440110.
52. Iacono, D., Geraci-Erck, M., Rabin, M.L., Adler, C.H., Serrano, G., Beach, T.G., Kurlan, R., Parkinson disease and incidental Lewy body disease: Just a question of time?. Neurology 85 (2015), 1670–1679, 10.1212/WNL.0000000000002102.
53. Ingelsson, M., Alpha-synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. Front Neurosci, 10, 2016, 408, 10.3389/fnins.2016.00408.
54. Jin, S.-G., Zhang, Z.-M., Dunwell, T.L., Harter, M.R., Wu, X., Johnson, J., Li, Z., Liu, J., Szabó, P.E., Lu, Q., Xu, G.-L., Song, J., Pfeifer, G.P., Tet3 Reads 5-carboxylcytosine through Its CXXC Domain and Is a Potential guardian against Neurodegeneration. Cell Reports 14 (2016), 493–505, 10.1016/j.celrep.2015.12.044.
55. Kanaan, N.M., Manfredsson, F.P., Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?. J Parkinsons Dis 2 (2012), 249–267, 10.3233/JPD-012138.
56. Kang, J.-H., Mollenhauer, B., Coffey, C.S., Toledo, J.B., Weintraub, D., Galasko, D.R., Irwin, D.J., Van Deerlin, V., Chen-Plotkin, A.S., Caspell-Garcia, C., Waligórska, T., Taylor, P., Shah, N., Pan, S., Zero, P., Frasier, M., Marek, K., Kieburtz, K., Jennings, D., Tanner, C.M., Simuni, T., Singleton, A., Toga, A.W., Chowdhury, S., Trojanowski, J.Q., Shaw, L.M., Parkinson's Progression Marker Initiative, CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol 131 (2016), 935–949, 10.1007/s00401-016-1552-2.
57. Kim, D.-K., Lim, H.-S., Kawasaki, I., Shim, Y.-H., Vaikath, N.N., El-Agnaf, O.M.A., Lee, H.-J., Lee, S.-J., Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. Autophagy 12 (2016), 1849–1863, 10.1080/15548627.2016.1207014.
58. Kim, C., Lv, G., Lee, J.S., Jung, B.C., Masuda-Suzukake, M., Hong, C.-S., Valera, E., Lee, H.-J., Paik, S.R., Hasegawa, M., Masliah, E., Eliezer, D., Lee, S.-J., Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril. Sci. Rep., 6, 2016, 30891, 10.1038/srep30891.
59. Klucken, J., Shin, Y., Masliah, E., Hyman, B.T., McLean, P.J., Hsp70 Reduces alpha-synuclein Aggregation and Toxicity. J Biol Chem 279 (2004), 25497–25502, 10.1074/jbc.M400255200.
60. Koike, M.A., Price, D.L., White, B.M., Rockenstein, E., Wrasidlo, W., Tsigelny, I., Meier, D., Masliah, E., Bonhaus, D.W., The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and Biochemistry in the murine thy1-ASYN transgenic model of Parkinson's disease. Soc. Neurosci., 2014.
61. Kramer, M.L., Schulz-Schaeffer, W.J., Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27 (2007), 1405–1410, 10.1523/JNEUROSCI.4564-06.2007.
62. Krishnan, R., Tsubery, H., Proschitsky, M.Y., Asp, E., Lulu, M., Gilead, S., Gartner, M., Waltho, J.P., Davis, P.J., Hounslow, A.M., Kirschner, D.A., Inouye, H., Myszka, D.G., Wright, J., Solomon, B., Fisher, R.A., A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. J Mol Biol 426 (2014), 2500–2519.
63. Lashuel, H.A., Overk, C.R., Oueslati, A., Masliah, E., The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14 (2013), 38–48, 10.1038/nrn3406.
64. Lee, H.-J., Bae, E.-J., Lee, S.-J., Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10 (2014), 92–98, 10.1038/nrneurol.2013.275.
65. Lee, J.M., Derkinderen, P., Kordower, J.H., Freeman, R., Munoz, D.G., Kremer, T., Zago, W., Hutten, S.J., Adler, C.H., Serrano, G.E., Beach, T.G., The Search for a Peripheral Biopsy Indicator of α-synuclein Pathology for Parkinson Disease. J. Neuropathol. Exp. Neurol. 76 (2017), 2–15, 10.1093/jnen/nlw103.
66. Lewis, J., Melrose, H., Bumcrot, D., Hope, A., Zehr, C., Lincoln, S., Braithwaite, A., He, Z., Ogholikhan, S., Hinkle, K., Kent, C., Toudjarska, I., Charisse, K., Braich, R., Pandey, R.K., Heckman, M., Maraganore, D.M., Crook, J., Farrer, M.J., In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener, 3, 2008, 19, 10.1186/1750-1326-3-19.
67. Lindholm, D., Pham, D.D., Cascone, A., Eriksson, O., Wennerberg, K., Saarma, M., c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease. Front Aging Neurosci, 8, 2016, 254, 10.3389/fnagi.2016.00254.
68. Lindström, V., Ihse, E., Fagerqvist, T., Bergström, J., Nordström, E., Möller, C., Lannfelt, L., Ingelsson, M., Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Immunotherapy 6 (2014), 141–153, 10.2217/imt.13.162.
69. Logan, T., Bendor, J., Toupin, C., Thorn, K., Edwards, R.H., α-Synuclein promotes dilation of the exocytotic fusion pore. Nat Neurosci 20 (2017), 681–689, 10.1038/nn.4529.
70. Lonskaya, I., Hebron, M.L., Desforges, N.M., Schachter, J.B., Moussa, C.E.H., Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med 92 (2013), 373–386, 10.1007/s00109-013-1112-3.
71. Lundblad, M., Decressac, M., Mattsson, B., Björklund, A., Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 109 (2012), 3213–3219, 10.1073/pnas.1200575109.
72. Ma, M.-R., Hu, Z.-W., Zhao, Y.-F., Chen, Y.-X., Li, Y.-M., Phosphorylation induces distinct alpha-synuclein strain formation. Sci. Rep., 6, 2016, 37130, 10.1038/srep37130.
73. Mahlknecht, P., Seppi, K., Poewe, W., The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis 5 (2015), 681–697, 10.3233/JPD-150685.
74. Majbour, N.K., Vaikath, N.N., van Dijk, K.D., Ardah, M.T., Varghese, S., Vesterager, L.B., Montezinho, L.P., Poole, S., Safieh-Garabedian, B., Tokuda, T., Teunissen, C.E., Berendse, H.W., van de Berg, W.D.J., El-Agnaf, O.M.A., Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener, 11, 2016, 7, 10.1186/s13024-016-0072-9.
75. Mao, X., Ou, M.T., Karuppagounder, S.S., Kam, T.I., Yin, X., Xiong, Y., Ge, P., Umanah, G.E., Brahmachari, S., Shin, J.H., Kang, H.C., Zhang, J., Xu, J., Chen, R., Park, H., Andrabi, S.A., Kang, S.U., Goncalves, R.A., Liang, Y., Zhang, S., Qi, C., Lam, S., Keiler, J.A., Tyson, J., Kim, D., Panicker, N., Yun, S.P., Workman, C.J., Vignali, D.A.A., Dawson, V.L., Ko, H.S., Dawson, T.M., Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.), 353, 2016 aah3374–aah3374 https://doi.org/10.1126/science.aah3374.
76. McCann, H., Stevens, C.H., Cartwright, H., Halliday, G.M., α-Synucleinopathy phenotypes. Parkinsonism Relat D, 20(Suppl. 1), 2014 S62–7 https://doi.org/10.1016/S1353-8020(13)70017-8.
77. McCormack, A.L., Mak, S.K., Henderson, J.M., Bumcrot, D., Farrer, M.J., Di Monte, D.A., Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia Nigra. PLoS ONE, 5, 2010, e12122, 10.1371/journal.pone.0012122.
78. McCormack, A.L., Mak, S.K., Di Monte, D.A., Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis., 3, 2012, e315, 10.1038/cddis.2012.50.
79. McLean, P.J., Kawamata, H., Shariff, S., Hewett, J., Sharma, N., Uéda, K., Breakefield, X.O., Hyman, B.T., TorsinA and heat shock proteins act as molecular chaperones: suppression of α-synuclein aggregation. J Neurochem 83 (2002), 846–854, 10.1046/j.1471-4159.2002.01190.x.
80. McNeill, A., Magalhaes, J., Shen, C., Chau, K.Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J.M., Abramov, A.Y., Gegg, M., Schapira, A.H.V., Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137 (2014), 1481–1495, 10.1093/brain/awu020.
81. Melki, R., Role of Different Alpha-synuclein Strains in synucleinopathies, Similarities with other Neurodegenerative Diseases. J Parkinsons Dis 5 (2015), 217–227, 10.3233/JPD-150543.
82. Migdalska-Richards, A., Schapira, A.H.V., The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem 139:Suppl. 1 (2016), 77–90, 10.1111/jnc.13385.
83. Migdalska-Richards, A., Ko, W.K.D., Li, Q., Bezard, E., Schapira, A.H.V., Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse, 71, 2017, e21967, 10.1002/syn.21967.
84. Mittal, S., Bjørnevik, K., Im, D.S., Flierl, A., Dong, X., Locascio, J.J., Abo, K.M., Long, E., Jin, M., Xu, B., Xiang, Y.K., Rochet, J.-C., Engeland, A., Rizzu, P., Heutink, P., Bartels, T., Selkoe, D.J., Caldarone, B.J., Glicksman, M.A., Khurana, V., Schüle, B., Park, D.S., Riise, T., Scherzer, C.R., β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science (New York, NY) 357 (2017), 891–898, 10.1126/science.aaf3934.
85. Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel-Döring, F., Ebentheuer, J., Trenkwalder, C., Schlossmacher, M.G., Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neuroscience Letters 532 (2013), 44–48, 10.1016/j.neulet.2012.11.004.
86. Mollenhauer, B., Batrla, R., El-Agnaf, O., Galasko, D.R., Lashuel, H.A., Merchant, K.M., Shaw, L.M., Selkoe, D.J., Umek, R., Vanderstichele, H., Zetterberg, H., Zhang, J., Caspell-Garcia, C., Coffey, C., Hutten, S.J., Frasier, M., Taylor, P., Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research, A user's guide for α-synuclein biomarker studies in biological fluids: perianalytical considerations. Mov Disord 32 (2017), 1117–1130, 10.1002/mds.27090.
87. Moors, T.E., Hoozemans, J.J.M., Ingrassia, A., Beccari, T., Parnetti, L., Chartier-Harlin, M.-C., van de Berg, W.D.J., Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener, 2017, 1–18, 10.1186/s13024-017-0154-3.
88. Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.S., Sidransky, E., Cooper, A., Garner, B., Halliday, G.M., Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137 (2014), 834–848, 10.1093/brain/awt367.
89. Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M., Schulte, C., Keller, M.F., Arepalli, S., Letson, C., Edsall, C., Stefansson, H., Liu, X., Pliner, H., Lee, J.H., Cheng, R., International Parkinson's Disease Genomics Consortium (IPDGC), Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Ashkenazi Jewish Dataset Investigator, Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE), North American Brain Expression Consortium (NABEC), United Kingdom Brain Expression Consortium (UKBEC), Greek Parkinson's Disease Consortium, Alzheimer Genetic Analysis Group, Ikram, M.A., Ioannidis, J.P.A., Hadjigeorgiou, G.M., Bis, J.C., Martinez, M., Perlmutter, J.S., Goate, A., Marder, K., Fiske, B., Sutherland, M., Xiromerisiou, G., Myers, R.H., Clark, L.N., Stefansson, K., Hardy, J.A., Heutink, P., Chen, H., Wood, N.W., Houlden, H., Payami, H., Brice, A., Scott, W.K., Gasser, T., Bertram, L., Eriksson, N., Foroud, T., Singleton, A.B., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (2014), 989–993, 10.1038/ng.3043.
90. Oueslati, A., Implication of Alpha-synuclein Phosphorylation at S129 in synucleinopathies: What Have We Learned in the Last Decade?. J Parkinsons Dis 6 (2016), 39–51, 10.3233/JPD-160779.
91. Pagan, F., Hebron, M., Valadez, E.H., Torres-Yaghi, Y., Huang, X., Mills, R.R., Wilmarth, B.M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S.L., Falconer, R.A., Ahn, J., Li, Z., Moussa, C., Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis 6 (2016), 503–517, 10.3233/JPD-160867.
92. Pampalakis, G., Sykioti, V.-S., Ximerakis, M., Stefanakou-Kalakou, I., Melki, R., Vekrellis, K., Sotiropoulou, G., KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget 8 (2017), 14502–14515, 10.18632/oncotarget.13264.
93. Parnetti, L., Paciotti, S., Eusebi, P., Dardis, A., Zampieri, S., Chiasserini, D., Tasegian, A., Tambasco, N., Bembi, B., Calabresi, P., Beccari, T., Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Parkinson's disease patients. Mov Disord, 35, 2017, 385, 10.1002/mds.27136.
94. Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., Baekelandt, V., α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (2015), 340–344, 10.1038/nature14547.
95. Peng, C., Gathagan, R.J., Lee, V.M.-Y., Distinct α-synuclein strains and implications for heterogeneity among α-synucleinopathies. Neurobiol Dis., 2017, 10.1016/j.nbd.2017.07.018.
96. Pierce, S., Coetzee, G.A., Parkinson's disease-associated genetic variation is linked to quantitative expression of inflammatory genes. PLoS ONE, 12, 2017 e0175882–11 https://doi.org/10.1371/journal.pone.0175882.
97. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.-E., Lang, A.E., Parkinson disease. Nat Rev Dis Primers, 3, 2017, 17013, 10.1038/nrdp.2017.13.
98. Postuma, R.B., Berg, D., Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12 (2016), 622–634, 10.1038/nrneurol.2016.152.
99. Postuma, R.B., Aarsland, D., Barone, P., Burn, D.J., Hawkes, C.H., Oertel, W., Ziemssen, T., Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease. Mov Disord 27 (2012), 617–626, 10.1002/mds.24996.
100. Prothena Company Website, Clinical results presented from Prothena's phase 1b study of PRX002/RG7935 demonstrating robust antibody CNS penetration and significant reduction of free serum alpha-synuclein in patients with Parkinson's disease. http://ir.prothena.com/releasedetail.cfm?ReleaseID=1019672, 2017.
101. Prothena Company Website, Prothena announces initiation of phase 2 PASADENA study of PRX002/RG7935 in patients with early Parkinson's disease. http://ir.prothena.com/releasedetail.cfm?ReleaseID=1032188, 2017.
102. Recasens, A., Dehay, B., Bové, J., Carballo-Carbajal, I., Dovero, S., Pérez-Villalba, A., Fernagut, P.-O., Blesa, J., Parent, A., Perier, C., Fariñas, I., Obeso, J.A., Bezard, E., Vila, M., Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75 (2014), 351–362, 10.1002/ana.24066.
103. Redmann, M., Wani, W.Y., Volpicelli-Daley, L., Darley-Usmar, V., Zhang, J., Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils. Redox Biology 11 (2017), 429–437, 10.1016/j.redox.2016.12.032.
104. Rey, N.L., Steiner, J.A., Maroof, N., Luk, K.C., Madaj, Z., Trojanowski, J.Q., Lee, V.M.-Y., Brundin, P., Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J. Exp. Med. 213 (2016), 1759–1778, 10.1084/jem.20160368.
105. Rey, N.L., Wesson, D.W., Brundin, P., The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol. Dis., 2016, 10.1016/j.nbd.2016.12.013.
106. Reynolds, A.D., Stone, D.K., Mosley, R.L., Gendelman, H.E., Nitrated α-synuclein-induced alterations in microglial immunity are regulated by CD4 + T cell subsets. J. Immunol. 182 (2009), 4137–4149, 10.4049/jimmunol.0803982.
107. Sanofi Genzyme Company Website, Sanofi initiates phase 2 clinical trial to evaluate therapy for genetic form of Parkinson's disease. http://news.genzyme.com/press-release/sanofi-initiates-phase-2-clinical-trial-evaluate-therapy-genetic-form-parkinsons-disea, 2017.
108. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, M.C., Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198 (2006), 382–390, 10.1016/j.expneurol.2005.12.024.
109. Sardi, S.P., Cheng, S.H., Shihabuddin, L.S., Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. Prog. Neurobiol. 125 (2015), 47–62, 10.1016/j.pneurobio.2014.12.001.
110. Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A., Rubinsztein, D.C., Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282 (2007), 5641–5652, 10.1074/jbc.M609532200.
111. Schenk, D.B., Koller, M., Ness, D.K., Griffith, S.G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., Kinney, G.G., First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 32 (2017), 211–218, 10.1002/mds.26878.
112. Schmid, A.W., Fauvet, B., Moniatte, M., Lashuel, H.A., Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteomics 12 (2013), 3543–3558, 10.1074/mcp.R113.032730.
113. Schrag, A., Horsfall, L., Walters, K., Noyce, A., Petersen, I., Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. 14 (2015), 57–64, 10.1016/S1474-4422(14)70287-X.
114. Shahnawaz, M., Tokuda, T., Waragai, M., Mendez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., Soto, C., Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74 (2017), 163–172, 10.1001/jamaneurol.2016.4547.
115. Shrivastava, A.N., Redeker, V., Fritz, N., Pieri, L., Almeida, L.G., Spolidoro, M., Liebmann, T., Bousset, L., Renner, M., Léna, C., Aperia, A., Melki, R., Triller, A., α-Synuclein assemblies sequester neuronal α3-Na +/K +-ATPase and impair Na + gradient. EMBO J. 34 (2015), e201591397–2423, 10.15252/embj.201591397.
116. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L.N., Condroyer, C., De Marco, E.V., Durr, A., Eblan, M.J., Fahn, S., Farrer, M.J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A.E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I.F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L.V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A.R., Tsuji, S., Wittstock, M., Wolfsberg, T.G., Wu, Y.-R., Zabetian, C.P., Zhao, Y., Ziegler, S.G., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361 (2009), 1651–1661, 10.1056/NEJMoa0901281.
117. Spencer, B., Michael, S., Shen, J., Kosberg, K., Rockenstein, E., Patrick, C., Adame, A., Masliah, E., Lentivirus mediated delivery of neurosin promotes clearance of wild-type. Mol. Ther., 2009, 1–11, 10.1038/mt.2012.66.
118. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., Masliah, E., Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29 (2009), 13578–13588, 10.1523/JNEUROSCI.4390-09.2009.
119. Stewart, T., Sossi, V., Aasly, J.O., Wszolek, Z.K., Uitti, R.J., Hasegawa, K., Yokoyama, T., Zabetian, C.P., Leverenz, J.B., Stoessl, A.J., Wang, Y., Ginghina, C., Liu, C., Cain, K.C., Auinger, P., Kang, U.J., Jensen, P.H., Shi, M., Zhang, J., Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathologica Communications, 3, 2015, 7, 10.1186/s40478-015-0185-3.
120. Stokholm, M.G., Danielsen, E.H., Hamilton-Dutoit, S.J., Borghammer, P., Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79 (2016), 940–949, 10.1002/ana.24648.
121. Sulzer, D., Alcalay, R.N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W.H., Mao, X., Dawson, V.L., Dawson, T.M., Oseroff, C., Pham, J., Sidney, J., Dillon, M.B., Carpenter, C., Weiskopf, D., Phillips, E., Mallal, S., Peters, B., Frazier, A., Arlehamn, C.S.L., Sette, A., T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 546 (2017), 656–661, 10.1038/nature22815.
122. Surmeier, D.J., Obeso, J.A., Halliday, G.M., Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18 (2017), 101–113, 10.1038/nrn.2016.178.
123. Thibault, L., Rascol, O., Corvol, J.-C., Ferreira, J., Defebvre, L., Deplanque, D., Bordet, R., Moreau, C., Devos, D., New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Mov. Disord., 2017, 10.1002/mds.27055.
124. Vellas, B., Carrillo, M.C., Sampaio, C., Brashear, H.R., Siemers, E., Hampel, H., Schneider, L.S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G.K., Fox, N., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P., Task Force Members, E.U/.U.S/.C.T.A.D., Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Presented at the Alzheimer's & Dementia: the Journal of the Alzheimer's Association, 2013, 438–444, 10.1016/j.jalz.2013.03.007.
125. Visanji, N.P., Mollenhauer, B., Beach, T.G., Adler, C.H., Coffey, C.S., Kopil, C.M., Dave, K.D., Foroud, T., Chahine, L., Jennings, D., Systemic Synuclein Sampling Study (S4), The systemic synuclein sampling study: toward a biomarker for Parkinson's disease. Biomark. Med 11 (2017), 359–368, 10.2217/bmm-2016-0366.
126. Wales, P., Pinho, R., Lázaro, D.F., Outeiro, T.F., Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J Parkinsons Dis 3 (2013), 415–459, 10.3233/JPD-130216.
127. Wang, C., Zhao, C., Li, D., Tian, Z., Lai, Y., Diao, J., Liu, C., Versatile structures of α-synuclein. Front. Mol. Neurosci., 9, 2016, 48, 10.3389/fnmol.2016.00048.
128. Watts, J.C., Giles, K., Oehler, A., Middleton, L., Dexter, D.T., Gentleman, S.M., Dearmond, S.J., Prusiner, S.B., Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19555–19560, 10.1073/pnas.1318268110.
129. Wong, Y.C., Krainc, D., Alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Publ. Group 23 (2017), 151–163, 10.1038/nm.4269.
130. Wyse, R.K., Brundin, P., Sherer, T.B., Nilotinib – differentiating the hope from the hype. J Parkinsons Dis 6 (2016), 519–522, 10.3233/JPD-160904.
131. Zharikov, A.D., Cannon, J.R., Tapias, V., Bai, Q., shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest., 2015, 10.1172/JCI64502.